Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma
Objective. Thyroid disease has been reported among the endocrinopathies that can occur after treatment with ipilimumab. Graves’ disease, however, has been rarely reported with this medication. Here we report a case of Graves’ disease diagnosed after initiation of ipilimumab in a patient with melanom...
Main Authors: | Umal Azmat, David Liebner, Amy Joehlin-Price, Amit Agrawal, Fadi Nabhan |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Case Reports in Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2016/2087525 |
Similar Items
-
IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2016-12-01) -
Profile of ipilimumab and its role in the treatment of metastatic melanoma
by: Patel SP, et al.
Published: (2011-12-01) -
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
by: Della Vittoria Scarpati G, et al.
Published: (2014-02-01) -
Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
by: Joanne M. Jeter, et al.
Published: (2012-07-01) -
Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
by: Joanne M. Jeter, et al.
Published: (2012-01-01)